Business Context and Reporting Period
Company: Globus Medical, Inc. (GMED)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Globus is a medical device company developing solutions for musculoskeletal disorders. The company operates globally with a portfolio divided into Musculoskeletal Solutions (implants, biologics, neuromonitoring) and Enabling Technologies (robotics, navigation, imaging).
Key Developments: The company completed the acquisition of Nevro Corp. on April 3, 2025, for approximately $252.5 million. This followed the 2023 acquisition of NuVasive. In 2025, Globus launched 9 new products, including the ExcelsiusXR extended reality navigation headset.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Net Sales | $2,938.9 million | $2,519.4 million |
| Operating Income | $479.8 million | $166.0 million |
| Net Income | $537.9 million | $103.0 million |
| Diluted EPS | $3.92 | $0.75 |
| Gross Margin (excl. amortization) | 67.4% | 58.9% |
| Operating Cash Flow | $753.4 million | $520.6 million |
| Cash and Cash Equivalents (Year End) | $526.2 million | $784.4 million |
| Total Debt | $0 (Convertible notes repaid) | $443.4 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 16.7% to $2.94 billion. U.S. sales grew 18.4% driven by Nevro contributions ($254.2 million) and organic growth in Musculoskeletal Solutions. International sales grew 10.0%.
- Profitability Surge: Net income increased 422% to $537.9 million. This was significantly aided by a non-taxable bargain purchase gain of $117.7 million recognized from the Nevro Merger.
- Cost of Sales: Decreased 7.5% to $957.8 million. This reduction was primarily due to the absence of the $215.4 million NuVasive inventory fair value step-up amortization recorded in 2024, partially offset by $91.2 million in Nevro cost of sales.
- SG&A Expenses: Increased 20.1% to $1.18 billion, largely due to $160.2 million in Nevro expenses and a $43.1 million accrual for the Pimenta litigation.
- Debt Reduction: The company repaid $450.0 million in Senior Convertible Notes in the first quarter of 2025. As of year-end, there were no outstanding borrowings under the revolving credit facility.
Guidance, Outlook, Risks, and Unusual Items
- Management Commentary: Management emphasizes the successful integration of NuVasive and Nevro, aiming to realize synergies. The company continues to expand its U.S. and international sales forces and invest in R&D for robotics and AI-driven solutions.
- Unusual Items:
- Bargain Purchase Gain: A $117.7 million gain from the Nevro acquisition significantly boosted 2025 net income.
- Legal Accrual: A $43.1 million provision for litigation was recorded in Q3 2025 related to the Pimenta case (breach of contract regarding royalties).
- Risks and Contingencies:
- Regulatory: An open FDA warning letter from July 2024 regarding complaint procedures for the ExcelsiusGPS robotic system remains unresolved as of February 2026.
- Legal: Ongoing patent infringement litigation with Moskowitz Family LLC (appeal pending) and 4WEB LLC. The Pimenta litigation resulted in a jury verdict against the company, though an appeal is planned.
- Market: Exposure to foreign exchange fluctuations (19.4% of sales are international) and potential tariff impacts on global supply chains.
Investor Verification Checklist
- Acquisition Integration: Verify the realization of synergies and cost savings from the NuVasive and Nevro mergers in upcoming quarters.
- Legal Exposure: Monitor the status of the Pimenta litigation appeal and the potential financial impact of the Moskowitz and 4WEB patent disputes.
- Regulatory Status: Confirm the resolution of the FDA warning letter regarding ExcelsiusGPS complaint procedures.
- Recurring Profitability: Assess operating margins excluding the one-time $117.7 million bargain purchase gain to understand core earnings power.
- Capital Allocation: Review the utilization of the $390 million remaining share repurchase authorization and future capital expenditure plans for surgical sets.